Gilead Sciences News

Company Name Stock Ticker Symbol Market Type
Gilead Sciences Inc GILD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.91 -1.43% 62.86 20:00:00
Open Price Low Price High Price Close Price Prev Close
63.49 62.30 63.785 62.86 63.77
more quote information »

Recent News

Date Time Source Heading
9/22/202208:30BWGilead Joins First-of-its-Kind Public-Private Initiative to..
9/20/202216:30BWGilead Sciences Completes Acquisition of MiroBio
9/16/202207:54DJNGilead Sciences Gets CHMP Backing for Expanded Yescarta Use
9/16/202207:46DJNGilead's Covid Drug Gets EU Regulator's Nod for Use on..
9/16/202207:00BWKite’s CAR T-cell Therapy Yescarta® First in Europe to..
9/16/202206:39BWCHMP Adopts Positive Opinion to Extend Indication of..
9/16/202200:15TRMNSVB Securities Keeps Their Hold Rating on Gilead Sciences..
9/15/202218:21BWWHO Expands Recommendation for Veklury® (Remdesivir) to..
9/13/202223:46TRMNRobert W. Baird Keeps Their Hold Rating on Gilead Sciences..
9/13/202211:28BWGilead Foundation Awards $20 Million to Organizations..
9/12/202216:10EDGARStatement of Changes in Beneficial Ownership (4)
9/12/202216:07EDGARStatement of Changes in Beneficial Ownership (4)
9/12/202216:04EDGARStatement of Changes in Beneficial Ownership (4)
9/12/202212:03DJNGilead Sciences Up Over 5%, on pace for Largest Percent..
9/12/202210:28TRMNGilead Sciences (NASDAQ:GILD) Ticks Higher After Settling..
9/12/202209:45TRMNMizuho Securities Reaffirms Their Buy Rating on Gilead..
9/12/202208:01EDGARCurrent Report Filing (8-k)
9/11/202201:55TRMNSVB Securities Sticks to Its Hold Rating for Gilead Sciences..
9/09/202221:45TRMNGilead Sciences (GILD) Gets a Buy from RBC Capital
9/07/202218:05BWTrodelvy® Significantly Improved Overall Survival in..
9/06/202218:30BWKite’s CAR T-cell Therapy Tecartus® Granted European..
9/06/202209:00TRMNHow Is Gilead (NASDAQ:GILD) Stock Positioned Ahead of ESMO..
9/05/202221:45TRMNRBC Capital Remains a Buy on Gilead Sciences (GILD)
8/29/202216:05BWGilead Sciences to Present at Upcoming Investor Conferences
8/29/202208:30BWGilead Demonstrates Strength of Oncology Portfolio Across..
8/22/202201:00BWGilead Announces First Global Regulatory Approval of..
8/17/202222:36TRMNGilead Sciences (GILD) Gets a Hold from SVB Securities
8/17/202211:00BWGilead Sciences Announces Collaboration With Morehouse..
8/15/202219:15BWGilead to Acquire Remaining Worldwide Rights of Trodelvy®
8/15/202212:24DJNGilead Sciences on Pace for Largest Percent Increase Since..
8/15/202208:30BWTrodelvy® Significantly Improves Overall Survival in..
8/09/202210:00BWGilead Sciences and a Coalition of LGBTQ+ and Human..
8/08/202216:45EDGARQuarterly Report (10-q)
8/04/202223:27TRMNGilead Sciences (GILD) Receives a Hold from Robert W. Baird
8/04/202223:27TRMNGilead Sciences (GILD) Gets a Hold Rating from SVB..
8/04/202215:15TRMNMaxim Group Reaffirms Their Buy Rating on Gilead Sciences..
8/04/202208:00BWGilead Sciences to Acquire MiroBio
8/03/202211:14DJNGilead Sciences Up Over 5%, on Pace for Largest Percent..
8/03/202208:18TRMNJefferies Thinks Gilead Sciences’ Stock is Going to Recover
8/03/202206:36TRMNNeedham Maintains Their Hold Rating on Gilead Sciences..
8/02/202217:04DJNGilead Sciences Updates Fiscal Year Outlook Following 2Q..
8/02/202216:55TRMNMizuho Securities Thinks Gilead Sciences’ Stock is Going to..
8/02/202216:50DJNGilead Sciences Posts Slightly Higher 2Q Sales
8/02/202216:07EDGARCurrent Report Filing (8-k)
8/02/202216:01BWGilead Sciences Announces Second Quarter 2022 Financial..
7/31/202218:12FNSStock Market Ahead: What to Expect Next Week
7/28/202213:30BWBiktarvy® Demonstrates High Efficacy for a Broad Range of..
7/26/202223:35TRMNGilead Sciences (GILD) Gets a Hold Rating from Robert W...
7/22/202210:36DJNGilead Sciences' Kite Unit Gets Positive CHMP Opinion for..
7/22/202209:42BWKite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP..

Your Recent History
Gilead Sci..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now